PFIZER
Executive Director – Drug Product Design & Development
Head – Nanoparticle Development
The Subcutaneous Drug Development and Delivery (SC) Consortium features a tiered membership structure, designed to promote participation tailored to the specific organization’s interest levels. The variety of membership options gives your company the flexibility to choose your level of engagement based on your technology interests and priorities.
Please find an overview of the membership structure in the table below.
$50,000 USD
Industry
Non-Industry
The Subcutaneous Drug Development and Delivery (SC) Consortium has no organization eligibility requirements – any type of organization can join as a Tier 1 or 2 Member.
Empower innovations, join us to shape the future of subcutaneous drug development together!
The Subcutaneous Drug Development and Delivery (SC) Consortium, herein SC Consortium, currently comprises six sub-teams, each working towards their own problem statements and research goals within the field:
Sustainability
Member organizations are allowed to change their tier of membership at any point in time. An organization that changes their membership tier is responsible for prorated dues for the remainder of the calendar year in order to serve as a Governing Board (Tier 1) member.
Tier 2 membership enables your organization to join as many sub-teams of interest.
Tier 1 members participate in bi-monthly Governing Board meetings, which is primarily held in virtual format with plans for occasional in-person meetings to discuss the strategic direction and ongoing activities of the Consortium.
Sub-teams have standing meetings at their own cadence for routine check-ins. These check-in meetings ensure each sub-team is actively making progress towards their planned activities and engagements, which revolve around their respective sub-team problem statements.
Tier 2 members routinely interact with Tier 1 members in all sub-team activities, in which all Governing Board members are active participants of the Consortium’s sub-teams. Sub-team activities do not distinguish membership tier with regards to participation on sub-team activities and all sub-team members work in tandem towards making progress on research problem statements.
In an effort, to advance the field of subcutaneous drug development and delivery, the Governing Board plans the strategic direction and research roadmap for sub-team activities at the beginning of each calendar year. Prior examples of sub-team activities that aim to address sub-team-specific problem statements include: landscape assessment, landscape monitoring, data synthesis, web scraping, scientific conference workshops, manuscript development and publication, quantitative and qualitative market research, etc.
The activities and efforts of the Subcutaneous Drug Development and Delivery Consortium provide an opportunity for participating organizations to proactively impact and drive value across SC drug development and delivery and ultimately provide value to the larger community.
Executive Director – Drug Product Design & Development
Head – Nanoparticle Development
Global Head Product Optimiatzation
SC Consortium CDRS Co-lead
Associate Director, Drug Delivery
SC Consortium Treasurer
Vice President, Dosage Form Design & Development
SC Consortium President
Senior Director, Astra Zeneca
SC Consortium Sustainability Co-lead
Global Head of Device Development Portfolio
Vice President
Head of Account and Business Development
Head
Scientific Excellence and Engagement Development